(Q87870251)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27402608%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

title

Single-Tube 10-Fluorochrome Analysis for Efficient Flow Cytometric Evaluation of Minimal Residual Disease in Plasma Cell Myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27402608%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27402608%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

author name string

Daniel J Royston

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27402608%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Qi Gao

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27402608%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Nghia Nguyen

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27402608%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Ahmet Dogan

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27402608%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Mikhail Roshal

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27402608%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

publication date

1 July 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27402608%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Clinical Pathology

18 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27402608%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

volume

146

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27402608%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27402608%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

page(s)

41-49

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27402608%20AND%20SRC:MED&resulttype=core&format=json

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

18 March 2020

cites work

1 reference

12 December 2020

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

1 reference

12 December 2020

Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy

1 reference

12 December 2020

Immunophenotyping of plasma cells

1 reference

12 December 2020

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

1 reference

12 December 2020

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m

1 reference

12 December 2020

Oncogenomics to target myeloma in the bone marrow microenvironment

1 reference

12 December 2020

A GEIL flow cytometry consensus proposal for quantification of plasma cells: application to differential diagnosis between MGUS and myeloma.

1 reference

12 December 2020

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

1 reference

12 December 2020

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.

1 reference

12 December 2020

Lenalidomide after stem-cell transplantation for multiple myeloma

1 reference

12 December 2020

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

1 reference

12 December 2020

Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity

1 reference

12 December 2020

Validation of cell-based fluorescence assays: practice guidelines from the ICSH and ICCS - part V - assay performance criteria.

1 reference

12 December 2020

Minimal residual disease: what are the minimum requirements?

1 reference

12 December 2020

Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposium

1 reference

12 December 2020

Controversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques

1 reference

12 December 2020

Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method

1 reference

12 December 2020

What we mean when we talk about MRD in myeloma. A review of current methods. Part 1 of a two-part series

1 reference

12 December 2020

Minimal residual disease in multiple myeloma: bringing the bench to the bedside

1 reference

12 December 2020

Identifiers

DOI

10.1093/AJCP/AQW052

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27402608%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27402608%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

PubMed publication ID

27402608

1 reference